CRA addressed issues relating to commercial success in patent litigation on behalf of an innovator company commercializing a drug for a rare disease. CRA addressed sales growth, profitability, and performance relative to other treatments for the same rare condition. In addition, CRA considered the characteristics of the product enabled by the patent in suit, taking into account clinical trial findings, product advantages reflected in company and public materials, and the company’s marketing activities.
12 CRA consultants named top IP professionals in the 2022 IAM Patent 1000
12 CRA consultants were recognized as leading patent professionals by Intellectual Asset Management (IAM). The IAM Patent 1000: The World’s Leading Patent...